COMPANY
Aligos Therapeutics
Timeline
- Trial start Phase 1: Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal source ↗
- Trial start Phase 1: Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Nor source ↗
- Trial start Phase 2: A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B source ↗
- Trial start 1: A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations source ↗
- Trial start Phase 1: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function source ↗
- Raise Private placement: $105M (total, as published), announced Feb 12, 2025. Source: SEC filing. source ↗
- Trial start Phase 1: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function source ↗
- Trial start Phase 1: A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers source ↗
- Trial start Phase 2: ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) source ↗
- Trial start 1: A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) source ↗
- Trial start 1: A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-09755 source ↗
- Trial start Phase 1: A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects source ↗
- Trial start Phase 1: A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia source ↗
- Trial start Phase 1: A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects source ↗
- Trial start Phase 1: A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects source ↗
- Trial start Phase 1: A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects source ↗
Upcoming milestones
- 2027-03 (ESTIMATED) · Phase 2 · A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) · NCT06963710
Funding
- Private placement: $105M (total, as published), announced Feb 12, 2025. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 15
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06963710 | A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | Phase 2 | Active, not recruiting | Jul 15, 2025 | 2027-03 (estimated) |
| NCT06698549 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function | Phase 1 | Completed | Feb 20, 2025 | Jul 23, 2025 (actual) |
| NCT07342868 | Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function | Phase 1 | Completed | Jan 30, 2026 | Aug 19, 2026 (actual) |
| NCT07342881 | Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function | Phase 1 | Completed | Mar 10, 2026 | Jul 29, 2026 (actual) |
| NCT06568861 | A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function | Phase 1 | Completed | Jan 13, 2025 | Jul 16, 2025 (actual) |
| NCT04536337 | A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects | Phase 1 | Completed | Oct 22, 2020 | Jun 16, 2025 (actual) |
| NCT06959888 | A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations | 1 | Completed | Mar 25, 2025 | May 8, 2025 (actual) |
| NCT05840952 | A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558 | 1 | Completed | Jul 4, 2023 | Apr 29, 2024 (actual) |
| NCT06191991 | A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) | 1 | Completed | Nov 3, 2023 | Nov 27, 2023 (actual) |
| NCT06342947 | ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) | Phase 2 | Completed | Apr 1, 2024 | Aug 19, 2024 (actual) |
| NCT06672900 | A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers | Phase 1 | Active, not recruiting | Jan 9, 2025 | Jul 7, 2025 (estimated) |
| NCT05561530 | A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects | Phase 1 | Terminated | Oct 7, 2022 | Jun 15, 2023 (actual) |
| NCT05090111 | A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia | Phase 1 | Completed | Dec 1, 2021 | Jun 16, 2023 (actual) |
| NCT05001022 | A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects | Phase 1 | Terminated | Sep 25, 2021 | Jul 18, 2022 (actual) |
| NCT04485663 | A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects | Phase 1 | Terminated | Aug 17, 2020 | Mar 8, 2022 (actual) |
NIH awards 3
- NIH contract (government contract; not a grant and not an investment round) 75N93023C00052-P00003-9999-1 FY2025: $1,516,140 awarded for that fiscal year; activity N01 (OTHER_NIH); PI WANG, STANLEY; recipient as written: ALIGOS THERAPEUTICS, INC., SOUTH SAN FRA source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N93023C00052-P00001-9999-1 FY2024: $1,300,776 awarded for that fiscal year; activity N01 (OTHER_NIH); PI WANG, STANLEY; recipient as written: ALIGOS THERAPEUTICS, INC., SOUTH SAN FRA source ↗
- NIH contract (government contract; not a grant and not an investment round) 75N93023C00052-0-9999-1 FY2023: $8,469,477 awarded for that fiscal year; activity N01 (OTHER_NIH); PI WANG, STANLEY; recipient as written: ALIGOS THERAPEUTICS, INC., SOUTH SAN FRANCISC source ↗
Raises and investors new
- Raise Private raise (SEC Form D): $105.0M sold; issuer “Aligos Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗